Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingenol Mebutate in Kidney Transplant Recipients with Actinic Keratosis
NCT02473848Phase 3Terminated
- Start
- Jun 2015
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ingenol mebutate in actinic keratosis (AK). Primary endpoint: Change in creatinine from baseline at 24 weeks. Started Jun 2015; status: terminated.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02473848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473848.